This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LH Stock to Gain From Launch of HPV and STI Self-Collection Options
by Zacks Equity Research
Labcorp launches self-collection options for HPV and STI testing in its PSCs.
ALGN Stock Gains From the Invisalign System With Mandibular Advancement
by Zacks Equity Research
Align Technology's Invisalign System, featuring mandibular advancement with occlusal blocks, is now commercially available for Class II malocclusion in the growing number of patients.
Is it Worth Retaining Thermo Fisher Stock in Your Portfolio Now?
by Zacks Equity Research
TMO continues to hold on to investors' attention due to its value-added acquisitions and trusted end-market channels.
Cardinal Health (CAH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) reachead $137.13 at the closing of the latest trading day, reflecting a -0.46% change compared to its last close.
GEHC Stock Gains Following Buyout Completion to Boost Its PDx Arm
by Zacks Equity Research
GE HealthCare aims to expand its existing footprint and offerings in Japan, as well as enhance patient access to next-generation radiopharmaceuticals via its latest acquisition.
GEHC Stock May Rise as Revolution Vibe CT Enhances Imaging Tech
by Zacks Equity Research
GE HealthCare introduces Revolution Vibe CT, a cutting-edge imaging system designed to enhance diagnostic precision, improve workflow efficiency, and expand accessibility.
ABT Stock to Gain From Early CE Mark Approval of Volt PFA System
by Zacks Equity Research
Abbott achieves early CE Mark approval for the Volt PFA system.
ABT Stock Gains Following the Positive TRILUMINATE Trial Results
by Zacks Equity Research
Abbott presents positive TRILUMINATE Pivotal trial data, which demonstrates TriClip system's safety and effectiveness at the ACC.25.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Thermo Fisher's New Deal With CZ Imaging Institute May Boost Its Stock
by Zacks Equity Research
TMO and CZ Imaging Institute to collaborate on further understanding of human cells.
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results
by Zacks Equity Research
ICCM reports strong kidney cancer cryoablation study results, showcasing 88.7% recurrence-free rates and reinforcing its position in cryoablation technology.
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
by Zacks Equity Research
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
International Expansion, Product Launches Support BSX Stock
by Zacks Equity Research
Boston Scientific continues to successfully expand its operations across various geographies outside the United States.
Intelligent Bio Solutions Stock Drops Despite Key U.S. Patent Win
by Zacks Equity Research
INBS secures a key U.S. patent, strengthening its IP protection and paving the way for 2025 market entry with innovative biometric technology.
Here's Why You Should Hold AVTR Stock in Your Portfolio for Now
by Zacks Equity Research
Avantor is set for growth with a strong portfolio and solid fourth quarter results, but challenges like customer losses and forex volatility pose potential risks.
Should Value Investors Buy Cardinal Health (CAH) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Forget Tech: Buy These 5 Non-Tech High Flyers of Q1
by Nalak Das
Here we discuss five non-tech stocks that have provided double-digit returns year to date, defying the negative trends of U.S. stock markets. These are TPR, WEC, CNP, CME and CEH.
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
by Zacks Equity Research
PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success.
Should You Retain Exact Sciences Stock in Your Portfolio Now?
by Zacks Equity Research
EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.
CAH Stock Rises More Than 13% YTD: Should You Buy, Hold or Sell?
by Zacks Equity Research
Cardinal Health's recent acquisitions and GMPD recovery look promising. However, the loss of the Optum Rx contract and margin pressure are likely to hurt short-term prospects.
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
by Zacks Equity Research
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
Cardinal Health (CAH) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Cardinal Health (CAH) closed at $133.98 in the latest trading session, marking a +0.93% move from the prior day.
Merit Medical Stock May Rise as WRAPSODY CIE Shows Strong Results
by Zacks Equity Research
MMSI unveils 12-month efficacy data for WRAPSODY CIE, highlighting its advanced technology in vascular access maintenance and potential to improve patient outcomes.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cardinal Health, Inc. (CAH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cardinal (CAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.